We also found several differences between the small molecule inhibitors and the monoclonal antibody targeting TGF-βRII: 1) LY2157299 displays similar functionalities and biochemical activities to those of LY2109761; 2) LY2157299 blocks migration and tumor growth in vitro independently of the expression levels of TGF-βRs, whereas D10 does not; 3) LY2157299 inhibits Smad-2 phosphorylation for a longer time than D10, and pSmad-2 is a key mediator of TGF-β1-triggered motility; 4) in patients with HCC, TGF-βRII is expressed in 33% of the cases. Here, SMAD2 is linked to neoplasm.